Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1)
- 1 October 2007
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 12 (19-20) , 838-843
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced MalignancyClinical Cancer Research, 2004
- Dose‐dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor ELBritish Journal of Clinical Pharmacology, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- SERIOUS INTERACTION BETWEEN MIBEFRADIL AND TACROLIMUS1Transplantation, 1998
- Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemiaLeukemia, 1997
- Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patientsAIDS, 1997
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994
- Digoxin toxicity due to interaction of digoxin with erythromycin.BMJ, 1989